- 1 Title: Algorithmic identification of treatment-emergent adverse events from clinical notes using large
- 2 language models: a pilot study in inflammatory bowel disease
- 3
- 4 Authors: Anna L Silverman, MD^{1,2,*}; Madhumita Sushil, PhD^{3,*}; Balu Bhasuran, PhD^{3,*}; Dana Ludwig,
- 5 MD³; James Buchanan, PharmD³; Rebecca Racz, PharmD⁴; Mahalakshmi Parakala⁵; Samer El-Kamary,
- 6 MD, MPH⁴⁺; Ohenewaa Ahima, MD⁴; Artur Belov, PhD⁴; Lauren Choi, PharmD⁴; Monisha Billings, DDS,
- 7 MPH, PhD⁴; Yan Li, B.Pharm, Ph.D.⁴; Nadia Habal, MD⁴; Qi Liu, PhD⁴; Jawahar Tiwari, PhD⁴; Atul J Butte,
- 8 PhD^{3,6}; Vivek A Rudrapatna, MD, PhD^{3,7}
- 9
- ¹Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA
- 11 ²Department of Medicine, University of California, San Diego, La Jolla, CA, USA
- 12 ³Bakar Computational Health Sciences Institute, San Francisco, CA, USA
- 13 ⁴ United States Food and Drug Administration, Silver Spring, MD, USA
- 14 ⁵Department of Public Health, University of California Berkeley, Berkeley, USA
- 15 ⁶Center for Data-Driven Insights and Innovation, University of California Health, Oakland, CA, USA
- 16 ⁷Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San
- 17 Francisco, San Francisco, CA, USA
- 18 ^{*}These authors contributed equally to this work and share first authorship.
- 19 + This work was done while at the FDA. Current affiliation University of Maryland School of Medicine,
- 20 Baltimore, MD , USA
- 21
- 22 Word Count: 3,599
- 23

24 Corresponding Author

- 25 Vivek A. Rudrapatna, MD, PhD
- 26 Assistant Professor of Medicine
- 27 University of California, San Francisco Bakar Institute, Box 2993
- 28 490 Illinois Street, Floor 2
- 29 San Francisco, CA 94143
- 30 Email: <u>vivek.rudrapatna@ucsf.edu</u>
- 31
- 32 Funding Source:
- 33 This publication was supported by the Food and Drug Administration (FDA) of the U.S. Department of
- Health and Human Services (HHS) as part of a financial assistance award Center of Excellence in
- Regulatory Science and Innovation grant to University of California, San Francisco, U01FD005978,
- totaling \$79,250 with 33% percentage funded by FDA/HHS and \$158,500, 66% percentage funded by the
- 37 UCSF Division of Gastroenterology and UCSF Bakar Computational Health Sciences Institute, and 1%
- 38 funded by the National Library of Medicine of the National Institutes of Health under Award Number
- 39 K99LM014099. Additional support for clinical data resources were provided by National Center for
- 40 Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number
- 41 UL1TR001872. The contents are those of the authors and do not necessarily represent the official views
- 42 of, nor an endorsement, by HHS or the U.S. Government.
- 43
- 44
- 45 **Disclosures**:

- 46 ALS: nothing to disclose
- 47 MS: nothing to disclose
- 48 BB: nothing to disclose
- 49 DL: nothing to disclose
- 50 JB: nothing to disclose
- 51 RR: nothing to disclose
- 52 MP: nothing to disclose
- 53 SE: nothing to disclose
- 54 OA: nothing to disclose
- 55 AB: nothing to disclose
- 56 LC: nothing to disclose
- 57 MB: nothing to disclose
- 58 YL: nothing to disclose
- 59 NH: nothing to disclose
- 60 QL: nothing to disclose
- 61 JT: nothing to disclose
- 62 AJB: AJB is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree
- 63 Corporation, and in the recent past, Samsung, 10x Genomics, Helix, Pathway Genomics, and Verinata
- 64 (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute,
- 65 Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a
- 66 shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet
- 67 (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma,
- 68 Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay
- 69 Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has

70	received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche,
71	Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca,
72	AbbVie, Westat, and many academic institutions, medical or disease specific foundations and
73	associations, and health systems. Atul Butte receives royalty payments through Stanford University, for
74	several patents and other disclosures licensed to NuMedii and Personalis. Atul Butte's research has
75	been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA,
76	Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan
77	and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of
78	Dimes, Juvenile Diabetes Research Foundation, California Governor's Office of Planning and Research,
79	California Institute for Regenerative Medicine, L'Oreal, and Progenity.
80	VAR: Receives grant support from Merck, Alnylam, Genentech, Stryker, Blueprint Medicines, Takeda,
81	and Janssen.
81 82	and Janssen. Involvement with the Manuscript:
81 82 83	and Janssen. Involvement with the Manuscript: Anna L. Silverman: study concept and design; acquisition of data; analysis and interpretation of data;
81 82 83 84	and Janssen. Involvement with the Manuscript: Anna L. Silverman: study concept and design; acquisition of data; analysis and interpretation of data; lead annotation protocol; lead drafting of the manuscript; lead critical revision of the manuscript for
81 82 83 84 85	and Janssen. Involvement with the Manuscript: Anna L. Silverman: study concept and design; acquisition of data; analysis and interpretation of data; lead annotation protocol; lead drafting of the manuscript; lead critical revision of the manuscript for important intellectual content
81 82 83 84 85 86	 and Janssen. Involvement with the Manuscript: Anna L. Silverman: study concept and design; acquisition of data; analysis and interpretation of data; lead annotation protocol; lead drafting of the manuscript; lead critical revision of the manuscript for important intellectual content Madhumita Sushil: co-lead model architect, study concept and design; acquisition of data; analysis and
81 82 83 84 85 86 87	and Janssen. Involvement with the Manuscript: Anna L. Silverman: study concept and design; acquisition of data; analysis and interpretation of data; lead annotation protocol; lead drafting of the manuscript; lead critical revision of the manuscript for important intellectual content Madhumita Sushil: co-lead model architect, study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important
81 82 83 84 85 86 87 88	 and Janssen. Involvement with the Manuscript: Anna L. Silverman: study concept and design; acquisition of data; analysis and interpretation of data; lead annotation protocol; lead drafting of the manuscript; lead critical revision of the manuscript for important intellectual content Madhumita Sushil: co-lead model architect, study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; technical support; implementation and model design
81 82 83 84 85 86 87 88 88	 and Janssen. Involvement with the Manuscript: Anna L. Silverman: study concept and design; acquisition of data; analysis and interpretation of data; lead annotation protocol; lead drafting of the manuscript; lead critical revision of the manuscript for important intellectual content Madhumita Sushil: co-lead model architect, study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; technical support; implementation and model design Balu Bhasuran: co-lead model architect, study concept and design; acquisition of data; analysis and
81 82 83 84 85 86 87 88 88 89 90	and Janssen. Involvement with the Manuscript: Anna L. Silverman: study concept and design; acquisition of data; analysis and interpretation of data; lead annotation protocol; lead drafting of the manuscript; lead critical revision of the manuscript for important intellectual content Madhumita Sushil: co-lead model architect, study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; technical support; implementation and model design; Balu Bhasuran: co-lead model architect, study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important

- 92 Dana Ludwig: study concept and design; acquisition of data; drafting of the manuscript; critical revision
- 93 of the manuscript for important intellectual content; technical support; implementation and model
- 94 design
- 95 James Buchanan: study concept and design; acquisition of data; analysis and interpretation of data;
- 96 critical revision of the manuscript for important intellectual content
- 97 Rebecca Racz: study concept and design; acquisition of data; analysis and interpretation of data; critical
- 98 revision of the manuscript for important intellectual content
- 99 Mahalakshmi Parakala: acquisition of data
- 100 Samer El-Kamary: lead investigator at the FDA for this project, administrative responsibility and study
- 101 team supervision at the FDA, intellectual contribution during the conduct of the study, and critical
- 102 revision of the manuscript for important intellectual content.
- 103 Ohenewaa Ahima: critical revision of the manuscript for important intellectual content; study
- 104 supervision
- 105 Artur Belov: critical revision of the manuscript for important intellectual content; study supervision
- 106 Lauren Choi: critical revision of the manuscript for important intellectual content; study supervision
- 107 Monisha Billings: critical revision of the manuscript for important intellectual content; study supervision
- 108 Yan Li: critical revision of the manuscript for important intellectual content; study supervision
- 109 Nadia Habal: critical revision of the manuscript for important intellectual content; study supervision
- 110 Qi Liu: critical revision of the manuscript for important intellectual content; study supervision
- 111 Jawahar Tiwari: critical revision of the manuscript for important intellectual content; study supervision
- 112 Atul Butte: study supervision
- 113 Vivek A Rudrapatna: study concept and design; acquisition of data; analysis and interpretation of data;
- 114 technical support; critical revision of the manuscript for important intellectual content; study
- 115 supervision

11	6	Disc	laimer:
	_		

- 117 The contents of this article reflect the views of the authors and should not be construed to represent
- 118 the FDA's views or policies. No official support or endorsement by the FDA is intended or should be
- 119 inferred.

- ____

138 Abstract

Background and Aims:

140 Outpatient clinical notes are a rich source of information regarding drug safety. However, data 141 in these notes are currently underutilized for pharmacovigilance due to methodological limitations in 142 text mining. Large language models (LLM) like BERT have shown progress in a range of natural language 143 processing tasks but have not yet been evaluated on adverse event detection. 144 Methods: 145 We adapted a new clinical LLM, UCSF BERT, to identify serious adverse events (SAEs) occurring 146 after treatment with a non-steroid immunosuppressant for inflammatory bowel disease (IBD). We 147 compared this model to other language models that have previously been applied to AE detection. 148 **Results:** 149 We annotated 928 outpatient IBD notes corresponding to 928 individual IBD patients for all SAE-150 associated hospitalizations occurring after treatment with a non-steroid immunosuppressant. These 151 notes contained 703 SAEs in total, the most common of which was failure of intended efficacy. Out of 8 152 candidate models, UCSF BERT achieved the highest numerical performance on identifying drug-SAE pairs 153 from this corpus (accuracy 88-92%, macro F1 61-68%), with 5-10% greater accuracy than previously 154 published models. UCSF BERT was significantly superior at identifying hospitalization events emergent to 155 medication use (p < 0.01). 156 Conclusions: 157 LLMs like UCSF BERT achieve numerically superior accuracy on the challenging task of SAE detection 158 from clinical notes compared to prior methods. Future work is needed to adapt this methodology to 159 improve model performance and evaluation using multi-center data and newer architectures like GPT.

160 Our findings support the potential value of using large language models to enhance pharmacovigilance.

- **Keywords:** pharmacovigilance, artificial intelligence, natural language processing, large language
- 162 models, BERT, adverse event detection, inflammatory bowel disease

- т, т

- . . .

182 Introduction

183 The accurate detection of treatment-emergent adverse events (AEs) is critical to ensure that 184 clinicians and patients can make well-informed treatment decisions that balance risks with benefits. This 185 is particularly true of non-steroid immunosuppressants which are commonly needed long-term for the 186 treatment of inflammatory bowel diseases (IBD). 187 Existing approaches for AE surveillance may involve prospective registry studies, spontaneous 188 postmarketing reporting (e.g., the Food and Drug Administration's AE Reporting System [FAERS])¹, 189 literature searches, and/or analyses of the structured data from claims and electronic health records 190 databases^{2,3}. These approaches have provided important data on the postmarket safety of medications but are limited by expense, small numbers, under/over-reporting^{4,5}, missing data, limitations in inferring 191 192 causality, and suboptimal sensitivity and specificity. Clinical notes are a rich source of AE data because 193 treating clinicians often document actions in response to potential AEs, including treatment 194 discontinuation and hospitalization. However, these notes have been underutilized for surveillance due 195 to methodological limitations in effective text mining. 196 Recent years have seen impressive advances in natural language processing following the release of 197 the large language model known as BERT (Bidirectional Encoder Representations from Transformers)⁶. 198 However, its adaptation to domain-specific arenas like medical language has been limited, in part due to 199 the unavailability of safe platforms for processing this protected health information until recently. In 200 prior work, our group of academic researchers has developed a new BERT model specifically designed to 201 interpret clinical text as typically documented in electronic health records (EHR) systems⁷. This model, 202 UCSF BERT, was trained on 75 million clinical notes documented across a range of specialties over the 203 last 10 years at the University of California, San Francisco (UCSF). Evaluations of UCSF BERT on several 204 general benchmarks show that it performs as well as or better than other comparable BERT models not specifically trained from scratch using a diverse corpus of notes derived from EHRs⁷. However, these 205

prior evaluations were general tasks and are limited by the quality of currently available, publiclybenchmarked tasks.

208	An open question motivating this study was whether the BERT model could help automate specific
209	tasks of established clinical importance, particularly one as challenging as AE detection. Many aspects
210	make the task of AE detection from clinical notes particularly difficult. These include the length of typica
211	clinical notes, the need to infer relationships between medications and documented AEs, to encode AEs
212	in a standardized way, and to overcome inherent vagueness in the documentation of clinical notes.
213	Some current examples of automated AE detection come from the National Natural Language
214	Processing Clinical Challenges (N2C2) ⁸ adverse event detection challenge, a nationwide clinical data
215	science competition that was held in 2018. Models from this competition were evaluated on highly
216	simplified benchmark tasks that do not reflect the typical patterns of clinical documentation such as
217	short snippets of notes rather than full length notes. Notably, none of the candidate models from the
218	competition were large language models as it was held prior to the wide-spread adoption of large
219	language models.
220	We hypothesized that adaptations of the UCSF BERT, a large language model, would outperform
221	previously published methods on multiple tasks related to AE detection, due in large part to its prior
222	training on a large volume of EHR notes. In this pilot study, we trained UCSF BERT to identify
223	hospitalization-associated serious adverse events (SAEs) from notes written in the outpatient IBD clinic,
224	and we compared its performance to a range of baselines including previously published models.
225	
226	Methods
227	Ethics

This single-center study of natural language processing algorithms for adverse event detection
was approved by the UCSF Institutional Review Board (#18-24588).

Target of prediction 230

231	The target of prediction was treatment-emergent, outpatient SAEs requiring hospitalization with
232	exposure to non-steroid immunosuppressant drugs for IBD, as documented in the outpatient
233	gastroenterology clinic notes at UCSF. The candidate list of drugs included all biologics and small-
234	molecule medications, except steroids, that were approved by the FDA for the treatment of ulcerative
235	colitis or Crohn's disease as of 2020, as well as off-label medications that are occasionally used to treat
236	these conditions. A complete list of included medications can be found in the supplemental materials.
237	Although the FDA's definition of SAEs includes multiple categories ⁹ , we limited our scope to only SAEs
238	associated with a hospitalization event, as these are more likely to be well-documented in clinical notes
239	due to their clinical importance. We defined treatment-emergent as an SAE that occurred while the
240	patient was actively receiving scheduled doses of a given medication, having been absent pre-
241	treatment. For example, if a patient was hospitalized for pneumonia 6 weeks after receiving an infusion
242	that was prescribed to be given every 8 weeks, the hospitalization event would be considered a
243	treatment-emergent SAE. Once the clinical decision to discontinue a given treatment plan was
244	documented, subsequent hospitalization events were no longer considered treatment-emergent SAEs.
245	Worsening of previously existing conditions that prompted hospitalization were included in line with
246	internationally used guidelines on AE reporting ¹⁰ . A definitive assessment of potentially causal
247	relationships between treatments and SAEs was beyond the planned scope of this analysis.
248	Document identification strategy
249	To identify the target notes for this study, we used a deidentified research database consisting
250	of structured EHR data at UCSF as well as clinical notes that had been subjected to automated redaction
251	of protected health information ¹¹ . We queried the database to identify all notes associated with the
252	gastroenterology department and an IBD diagnosis code (ICD-9 555/556; ICD-10 K50/K51). We selected
253	notes written between $1/1/2018$ and $12/31/2020$ and utilized the most recent note for each patient

10

notes written between 1/1/2018 and 12/31/2020 and utilized the most recent note for each patient

who was at least 18 years old during this period. We selected this timeframe to maximize the capture of
a wide range of FDA-approved treatments. We used the most recent note per patient to avoid double
counting SAEs mentioned in multiple notes, and to take advantage of the fact the documented histories
tend to be inclusive of prior events. All included notes were written by a gastroenterology physician or
advanced practice provider in the IBD outpatient clinic. *Document Preprocessing*

260 The history of present illness (HPI) section of the notes was extracted using rule-based approaches

261 developed specifically for this project (supplemental methods). The HPI section of the note was the only

262 portion of the note utilized for downstream analysis as this section of the note often contains a

263 cumulative source of information on treatment exposures and outcomes, particularly out-of-system

264 events (i.e., hospitalizations and SAEs that occurred outside of UCSF but were relayed to the

265 gastroenterology provider at the time of routine follow-up). The HPI was pre-labeled with medications

of interest, hospitalization and signs and symptoms using, named entity recognition functions, from the

267 clinical natural language processing software *cTAKES*¹², as well as regular expressions (i.e., the ability to

268 locate pre-defined key-words). To minimize downstream algorithmic confusion in learning medication

269 names, the medication brand names were replaced with the generic name using the RxNorm

270 Application Program Interfaces (APIs) in Unified Medical Language System (UMLS)¹³.

271 Note Annotation

All notes that met the above inclusion criteria were annotated to fine-tune UCSF BERT on a variety of AE detection-related tasks and to evaluate its performance against comparator models. A team of five annotators, consisting of gastroenterologists, pharmacists, pharmacovigilance experts, and patients carried out all annotation related tasks. These included the development and finalization of an annotation protocol, participation in interrater reliability assessments, and annotation of all target notes. The annotation protocol was collectively developed and refined over the course of weekly team

meetings utilizing an initial subset of notes. Using LabelStudio¹⁴, an open-source annotation platform, 278 279 annotators marked up the prelabelled HPI section of candidate notes according to triplets of medication 280 mentions, hospitalization mentions, and SAE mentions, if they corresponded to a hospitalization as per 281 the protocol (supplemental methods) (Figure 1). These annotations became the basis of the subsequent 282 efforts to train UCSF BERT and other models to automate this process. 283 All five annotators participated in an interrater reliability assessment on a sample of 19 notes. The 284 results of these assessments were reviewed in weekly meetings to improve the protocol as well as 285 annotator compliance to it. We computed a Fleiss' kappa statistic to characterize the interrater 286 reliability on the final round of assessments. Following this training and assessment phase, the protocol 287 was locked, and the remainder of the corpus was annotated. 288 289 Modeling 290 We defined several prediction tasks, asking the model to classify whole HPIs according to the 291 occurrence of: (task 1) all candidate medication mentions given prior to a hospitalization (task 2) 292 adverse event (AE) as reason for hospitalization and (task 3) the combination of task 1 and task 2 the 293 medication-hospitalization-AE triple (Figure 1). We trained models of different architectures to 294 determine which were best suited for the task of AE detection. We used scikit-learn¹⁵ to train several 295 baseline Bag of Words (BoW) models such as Logistic Regression, K-Nearest Neighbors, Decision Trees, Random Forest, and XGBoost (supplemental methods). We used AutoGluon¹⁶ to train the automated 296 297 machine learning models. The annotated notes were split into 80% training, 10% validation and 10% 298 testing. These served as a baseline to compare the performance of our UCSF BERT model. We adapted 299 deep learning models architectures such as Convolutional Neural Network (CNN^{17,18}), Bidirectional Long Short Term Memory Network (Bi-LSTM¹⁹) and Bi-LSTM with attention. These are deep learning models 300 301 adapted from the top performing entries in the N2C2⁸ adverse event detection challenge. All BERT 302 results are from the median performance of Macro F1 score over 5 runs of the model with different

303 seeds. Comparative model performance significance was evaluated using Fisher's exact test and chi

304 square with Yates's correlation when values were large enough to require it.

- 305 Note Length Handling
- To include the entire HPI section, which was often longer than the typical maximum input length

307 used by other BERT models, we developed a hierarchical version of the UCSF-BERT²⁰ model (H-UCSF-

BERT). This model learns to process text using input sequences of 512 tokens (roughly equivalent to

309 words), in the same manner as a typical BERT model would. It then combines them into a longer-

310 sequence representation by integrating an additional transformer layer on top of these chunk

representations. We encoded sequences up to 2560 tokens, which is 5 times the usual processing limit

- of a BERT model. We used the Mann-Whitney test to evaluate the possible association between note
- 313 length and the presence of SAEs.
- 314 Handling of Class Imbalance

315 SAEs were seen in 44% of notes in our corpus, however SAEs were uncommon once the notes 316 were subdivided into chunks that were ingestible by H-UCSF-BERT, creating a potential problem for 317 training models to learn to positively identify these SAEs when they do occur. To optimize learning in the face of this imbalance in the dataset, the training data examples without AEs were randomly 318 319 undersampled. We explored a range of sampling ratios and identified the ratio of 1:4 positive to 320 negative examples as being best for model performance. This was applied to the training dataset for all 321 downstream tasks. We also explored additional strategies such as weighting the optimization loss based on class distributions, as well as learning these weights dynamically²¹. However, we obtained the most 322 323 promising result by undersampling the majority dataset.

324 MedDRA

All SAEs were manually coded using the Medical Dictionary for Regulatory Activities (MedDRA)
 version 23.0²².

327 Results

328 Source Corpus, Patient Population, and SAE Dataset

329 From a deidentified dataset of 110 million machine redacted clinical notes at UCSF, we 330 identified a total of 928 notes corresponding to 928 adults with IBD who were seen during the 2018-331 2020 period. The patients in our study were 53% female with an average age of 45 years old (Table 1). 332 The most common race of patients was white. We annotated all 928 notes and performed interrater 333 reliability testing on a set of 19 notes to characterize the quality of the annotated dataset. The mean 334 observed agreement among the five annotators was 93-99% across all annotation categories 335 (Supplemental Table 1). 336 We identified a total of 703 SAEs in the 928 annotated notes from 928 patients with IBD. All 337 SAEs were associated with hospitalization as defined by the annotation protocol. Out of the 928 338 annotated notes, 411 documented at least one SAE (Table 2 and Supplemental Table 3). Importantly, 339 some notes included more than one SAE due to multiple distinct hospitalizations in the note. The notes 340 documenting an SAE tended to be longer than those without an SAE (p<0.001). Over 60% of SAEs in our 341 corpus were associated with anti-tumor necrosis factor agents (anti-TNF). Infliximab was associated with 342 179 SAEs, the most of any drug, followed closely by adalimumab (136 SAEs; Table 3). This finding was 343 expected given that infliximab was the first biologic to be approved for IBD, and more patients have 344 been exposed to this medication than any other due to its longer availability. Additionally, given the 345 relative absence of alternative treatments in the early 2000s, it is likely that patients remained on 346 infliximab and other anti-TNFs for a longer period (even after experiencing SAEs), compared to the 347 current era with multiple approved medications. The most common SAE was failure of intended efficacy 348 (N=299), followed by infections (N=94) (Figure 2 and Table 4). However, SAEs were found for every 349 organ system and every non-steroid immunosuppressant. Our corpus contained only one episode of 350 cancer, sarcoma, which occurred in a patient receiving an anti-TNF drug. The complete list of SAEs

351 mapped by clinical note terms and MedDRA terms can be found in the supplemental materials

- 352 (Supplemental Table 3). However, to enable a more user-friendly exploration of trends in the data, we
- 353 have developed an interactive web application (see <u>https://ibd-ade.streamlit.app/</u>).
- 354 Performance of UCSF-BERT on the Task of SAE Detection
- We established three targets of prediction for all downstream models: (task 1) identify all
- 356 candidate medication mentions given prior to a hospitalization, (task 2) identify adverse event as reason
- for hospitalization and (task 3) the combination of task 1 and task 2 the medication-hospitalization-AE
- triple (Figure 1). The annotated data was transformed and then split into training, validation, and testing
- datasets for each of these binary classification tasks (Table 2 and Supplemental Table 2). We developed
- and trained several variations of the UCSF-BERT model to address each of these targets. We then
- 361 evaluated its performance against several other comparator models, including several of the top entries
- 362 from the 2018 N2C2 adverse event detection challenge (supplemental methods).

363 On the task of medication prior to hospitalization, H-UCSF-BERT was the most performant model 364 with a Macro F1 of 62% (Table 5). It was significantly more accurate than the next-best model by a 365 margin of 11% (p < 0.01). Similarly, H-UCSF-BERT was the best model at the task of identifying 366 hospitalization relations to AEs with an accuracy of 96% and Macro F1 of 62%. We hypothesized that 367 long distances between mentions of a hospitalization and the associated SAEs could be reducing model 368 accuracy. Indeed, we found that restricting the input to SAEs mentioned within a two-sentence span of 369 the hospitalization, Macro F1 increased to 68% from 62% (p < 0.01). However, when compared to the 370 next performant model, BiLSTM, UCSF BERT was not significantly superior (p = 0.40). The ultimate goal 371 was to have our model accurately detect triples which include the mention of a non-steroid 372 immunosuppressant prior to a hospitalization plus the hospitalization plus the associated SAEs. For the 373 triples task, H-UCSF-BERT was again the best performer with a Macro F1 of 61%, however again this was 374 not significantly different than BiLSTM (p= 0.40).

375 Discussion

376 We adapted an EHR-specific clinical language model, UCSF BERT, to multiple tasks pertaining to 377 the detection of treatment-emergent serious adverse events. We have evaluated its performance in the 378 context of a specific use case: the use of non-steroid immunosuppressants for the treatment of IBD. We 379 have generated a gold standard corpus of 928 clinical notes as the basis of training and evaluating this 380 model against several baselines. Inter-rater reliability testing indicates good to excellent concordance 381 across annotators. UCSF BERT performed well in a range of tasks pertaining to SAE detection from 382 clinical notes. It achieves macro F1 scores ranging from 61-68% and accuracies from 88-92%, This model 383 numerically outperforms existing models for SAE detection associated with the N2C2 Challenge⁸ as well 384 as a range of strong baseline models, including several trained using automated machine learning. On 385 the task of accurately determining a medication of interest mentioned prior to a hospitalization, UCSF 386 BERT was significantly superior to all other models. 387 We found that the most common errors made by the models involved chains of reasoning

across many events. For example, instances where the reason of hospitalization is not explicitly mentioned but merely implied from the clinical context. In addition, the model struggled in the setting of both long-distance dependency where there were many sentences between entities of interest and long chronology of events where several medication changes occurred over many sentences. Lastly, when there were both non-specific adverse events such as pain or vomiting as well as more specific terms such as small bowel obstruction or ulcerative colitis flare the combination was challenging for the model to handle.

The last few decades have seen a significant expansion in FDA-approved therapies for IBD. In the current era of IBD treatment with numerous agents available, continued monitoring for new safety information on these agents is helpful to inform optimal treatment selection. The most frequent SAE found in our corpus of outpatient IBD clinical notes at a tertiary referral center was failure of intended

399 efficacy followed by infections. This is in line with previously published data, especially in the setting of more than 60% of the SAEs in our corpus associated with anti-tumor necrosis factor agents²³. We did not 400 401 account for concurrent use of steroids which are known to increase the risk of infection. However, our 402 corpus includes SAEs from every organ system. Of note, the non-steroid medications of interest are not 403 being prescribed with equal frequency; thus, prescribing practices are likely to influence the frequency 404 of events as well as frequencies of possible AEs associated with the medication. The strength of 405 association with SAEs and classes of non-steroid immunosuppressants can be explored using our 406 interactive web application (see https://ibd-ade.streamlit.app/). The goal of developing text-based 407 automation tools like this is to enable more precise characterizations of adverse events in the context of 408 routine clinical care to help validate known safety profiles of these drugs as well as identify previously 409 unrecognized SAEs which can point to areas of inquiry. For instance, our dataset included a patient 410 receiving an anti-TNF who was hospitalized for a new diagnosis of sarcoma. Sarcomas have previously been reported in the context of children with IBD using anti-TNFs²⁴, although multiple long-term 411 412 observational studies have not consistently found a link between anti-TNF use and an increased risk of cancer in adults^{25,26}. Future directions of this work include external validation using data from additional 413 414 centers, expansion to additional disease states outside of IBD, and downstream studies designed to 415 identify new drug-SAEs associations more rigorously using aggregated data. 416 Our work has many notable strengths. We have used transparent methods for developing the 417 training corpus and assessing its quality, including interrater reliability. Because our models have been 418 trained on de-identified clinical data, we intend to make them publicly available for others to reproduce 419 and enhance multiple aspects of this work. Of note, the N2C2 national challenge which produced

420 models for detection of treatment-emergent adverse events from clinical notes prior to our work was

421 before the release of BERT. We suspect that the underlying architecture of BERT in addition to our pre-

422 training from scratch on a sizeable clinical corpus are driving our improved performance compared to423 prior models.

424	Some limitations of our work, outside of those common to retrospective research, include
425	imperfect accuracy of the model, which on certain tasks did not perform statistically significantly
426	superior to other models. We suspect this largely the result of long-distance dependance and long
427	chains of reasoning across many events in a clinical note. In addition, we have not yet assessed the
428	generalizability of our model across other diseases, treatments, or health systems. As well, our
429	interrater agreement is potentially optimistic as it was calculated iteratively on the same 19 notes.
430	However, there are no universally accepted standards of the Fleiss' kappa statistic ²⁷ for good
431	agreement. Future work aimed at improving upon our current model includes annotating a lager corpus
432	at an outside health system to evaluate generalizability and over-sampling for SAEs to have more
433	positive examples for the model to learn from. Overall, our approach, utilizing novel methods from the
434	field of artificial intelligence, has the potential to address unmet needs in drug safety surveillance, an
435	area of central importance to regulatory agencies across the globe and to public health in general.
436	Conclusion
437	We have successfully adapted a new clinical language model, UCSF BERT, to the task of mining
438	outpatient clinic notes for SAEs occurring in patients with IBD administered non-steroid
439	immunosuppressants. This model performs well on the tasks of SAE detection, especially identifying
440	target medications prior to hospitalizations. The success of this model appears to stem from its
441	pretraining on a large and diverse corpus of notes derived from real-world clinical care and use of
442	hierarchical modeling which allows for long sequence document classification tasks. These results
443	suggest the feasibility of adapting artificial intelligence methods to address important unmet needs in
444	the field of pharmacovigilance, with the potential to substantially reduce the manual efforts needed to
445	review notes and identify events of concern. Our work is a step closer to a future of automated drug

- 446 surveillance algorithms embedded within EHR systems which can facilitate pharmacovigilance activities
- 447 ranging from health system reporting of SAEs to large-scale safety evaluations across multiple EHR
- 448 systems without the limitations of using billing codes as surrogates for actual AEs.
- 449 **Study Highlights**
- What is the current knowledge on the topic?
- 451 o Prior work in automated adverse event (AE) detection from routine clinic notes utilized note
- 452 fragments and simplified AE detection tasks. In addition, the newest model architectures
- 453 were not widely available when automated AE detection was evaluated in a national natural
- 454 language processing challenge in 2018.
- What question did this study address?
- 456 Are the newest model architectures trained on clinical notes capable of detecting serious
- 457 AEs in routine clinical notes as written by clinicians seeing patients with inflammatory bowel
- 458 diseases at a tertiary medical center.
- What does this study add to our knowledge?
- 460 o Our model, UCSF BERT, trained on a large corpus of real-world clinical notes performs better
- 461 than prior models previously designed for this task. Notably, our hierarchical model
- 462 architecture is able to digest information five times the usual processing limit of BERT.
- How might this change clinical pharmacology or translational science?
- 464 o Our work is a step closer to a future of automated drug surveillance algorithms embedded
 465 within EHR systems which can facilitate pharmacovigilance activities.

466 Access to Data:

- 467 The analytic code to train and evaluate models will be made publicly available at
- 468 https://github.com/MadhumitaSushil/ADE_detection. A machine-redacted version of the notes-based

469 data can be made available to requesting researchers by mutual agreement and following the execution

- 470 of a data use agreement.
- 471 Acknowledgements:
- 472 We gratefully acknowledge the invaluable administrative support provided by Lily Wong. In
- 473 addition, we would like to acknowledge the UCSF Information Commons Computational Research
- 474 Platform, developed and supported by UCSF Bakar Computational Health Sciences Institute and UCSF
- 475 Academic Research Services. We would like to express our thanks to the Wynton support team and the
- 476 UCSF high-performance computing cluster, Wynton.
- 477 Citations
- 478

479		
480	1.	Questions and Answers on FDA's Adverse Event Reporting System (FAERS).
481		https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-
482		<u>reporting-system-</u>
483		faers#:~:text=The%20FDA%20Adverse%20Event%20Reporting,that%20were%20submitt
484		<u>ed%20to%20FDA</u> . Accessed 05/19/2023.
485	2.	Thein D, Egeberg A, Skov L, Loft N. Absolute and Relative Risk of New-Onset Psoriasis
486		Associated With Tumor Necrosis Factor- α Inhibitor Treatment in Patients With Immune-
487		Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study. JAMA
488		dermatology. 2022.
489	3.	Chaparro M, Garre A, Ricart E, et al. Short and long-term effectiveness and safety of
490		vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
491		Alimentary pharmacology & therapeutics. 2018;48(8):839-851.
492	4.	Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug safety.
493		2006;29(5):385-396.
494	5.	Varallo FR, Guimarães SdOP, Abjaude SAR, Mastroianni PdC. Causes for the
495		underreporting of adverse drug events by health professionals: a systematic review.
496		Revista da Escola de Enfermagem da USP. 2014;48:739-747.
497	6.	Devlin J, Chang M-W, Lee K, Toutanova K. Bert: Pre-training of deep bidirectional
498		transformers for language understanding. <i>arXiv preprint arXiv:181004805</i> . 2018.
499	7.	Sushil M, Ludwig D, Butte AJ, Rudrapatna VA. Developing a general-purpose clinical
500		language inference model from a large corpus of clinical notes. arXiv preprint
501		arXiv:221006566. 2022.
502	8.	Henry S, Buchan K, Filannino M, Stubbs A, Uzuner O. 2018 n2c2 shared task on adverse
503		drug events and medication extraction in electronic health records. Journal of the
504		American Medical Informatics Association. 2019;27(1):3-12.

505 506	9.	Code of Federal Regulations Title 21. In: Administration USFaD, ed. <i>Title 21, Volume 5,</i>
500	10	ZIGRASIZ.SZ. Agonov FM JCH Tonic F9 Statistical Principles for Clinical Trials
508	10.	https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-
500		nripsinlos clinical trials ston 5 on ndf
510	11	Norgoot R. Muonzon K. Dotorson TA, et al. Protected Health Information filter (Philter):
510	± ±.	accurately and securely de identifying free text clinical notes. NPI digital medicine
512		
512	10	2020,5(1).57. Sayaya GK, Masanz II, Ogran DV, at al. Maya clinical Taxt Analysis and Knowledge
515	12.	Savova GK, Masaliz JJ, Oglell PV, et al. Mayo clinical text Analysis and Knowledge
514		Lournal of the American Medical Informatics Association, 2010:17/E):E07 E12
515	12	Bodonroidor O. The unified modical language system (UMLS): integrating biomodical
	15.	terminology Nucleic acids research 2004-22/suppl 1) D267 D270
51/ E10	14	terminology. Nucleic uclus research. 2004;52(suppl_1).D207-D270.
510	14. 1c	Luber Studio. Duta Labering Software [computer program]. 2020-2022.
219	15.	the lowred of machine Learning research 2011:12:2825 2820
520	16	Erickson N. Mueller I. Shirkey A. et al. Autogluon tabulary Behyst and accurate autom
521	10.	for structured data, arXiv proprint arXiv/200206505, 2020
522	17	Tor structured data. <i>arxiv preprint arxiv:200306505</i> , 2020.
523	17.	Lecun Y, Bollou L, Bengio Y, Hanner P. Graulent-based learning applied to document
524	10	Pecognition. Proceedings of the rece. 1998;86(11):2278-2324.
525	18.	Yann Lecun BB, John Denker, Donnie Henderson, R. Howard, Wayne Hubbard, Lawrence
520		Jackel. Handwritten Digit Recognition with a Back-Propagation Network. Paper
527	10	presented at: Advances in Neural Information Processing Systems 21989.
528	19.	Hochreiter S, Schmidnuber J. Long Short-Term Memory. <i>Neural Comput.</i>
529	20	1997;9(8):1/35–1/80.
530	20.	JI S, Holita W, Wartinen P. Does the magic of BERT apply to medical code assignment?
531	21	A quantitative study. Computers in Biology and Medicine. 2021;139:104998.
532	21.	Detected From Impalanced
533	22	Datasets. Frontiers in big Data. 2021;4:715320.
534	22.	Wealcal Dictionary for Regulatory Activities [computer program].
535	23.	Quezada Sivi, MicLean LP, Cross RK. Adverse events in IBD therapy: the 2018 update.
536	24	Expert Review of Gastroenterology & Hepatology. 2018;12(12):1183-1191.
537	24.	Anderson K, Moss K, Campbell B, Moote D, Kakazu K, Hyams JS. Follicular Dendritic Cell
538		Sarcoma in a Patient with Adolescent-Unset Cronn's Disease Exposed to Multiple
539	25	Immunomodulator and Biologic Therapies. JPGIV Reports. 2022;3(3):e231.
540	25.	Smith IVI. Anti-TNF α therapy did not increase short-or medium-term risk for cancer in
541	26	patients with rheumatoid arthritis. Annais of Internal Medicine. 2010;152(20):JC5-13.
542	26.	Conti F, Atzeni F, Massaro L, et al. The influence of comorbidities on the efficacy of
543		tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on
544		comorbidities in rheumatoid arthritis: report from a National Consensus Conference.
545	27	Kneumatology. 2018;57(Supplement_7):VII11-VII22.
546 547	27.	Statsmodels [computer program]. 2009-2022.
547 578		
547 548		

549 Figure and Table Legends

550

551 **Figure 1.** Example of the three prediction tasks from a clinical note in the corpus. Medications of interest

were pre-annotated in blue, hospitalizations in red and signs and symptoms in yellow. Annotators

553 marked up the HPI section where medications of interest predated a hospitalization (green and blue

arrow) and AE causing hospitalization (red arrow). Task 3, also referred to as triple, is the combination of
 Task 1 and Task 2.

556

557 **Table 1.** Characteristics of patients in our note corpus

558 **Table 2.** Distribution of number of notes containing an SAE

Table 3. Distribution of hospitalizations and SAEs by medication. Anti-tumor necrosis factor (Anti-TNF),
 Janus Kinase-inhibitor (JAK-inhibitor), anti-interleukin-12/23 (anti-IL-12/23).

561

Table 4. Top 7 SAEs in the Study. Anti-tumor necrosis factor (Anti-TNF), Janus Kinase-inhibitor (JAKi),
 anti-interleukin-12/23 (anti-IL-12/23).

564

Figure 2. Network Graph of SAEs by medication class. The width of lines indicates the strength of
association by frequency. The size of the nodes is relative to the number of exposures in our corpus to
each medication. SAE colors are indicative of which medication(s) they were associated with. An
interactive version of this figure can be found at https://ibd-ade.streamlit.app/

569

570 **Table 5.** Results of UCSF BERT performance on the tasks of SAE detection from real world clinical notes.

871 Results for the three relation tasks to classify whether a pair/triple of specific entities of type

572 medication, hospitalization and adverse event are related. Bolded models correspond to those with the

best performance as measured by Macro F1. Only nearby SAEs refer to restricting only SAEs that are

574 mentioned within a two-sentence window of the hospitalization event. Only the best three models are

575 reported. H-UCSF-BERT = Hierarchical University of California San Francisco Bidirectional Encoder

576 Representation from Transformers, TP = true positive, TN = true negative, FP = false positive and FN =

577 false negative.

578

medRxiv preprint doi: https://doi.org/10.1101/2023.09.06.23295149; this version posted September 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. **Figures and Tables** Task 1: medication before Despite escalated adalimumab dosing (40 mg weekly and later 80 mg Q2 hospitalization weeks) she remains symptomatic. Her most recent colonoscopy on adalimumab 80mg Q2 weeks showed pancolitis. She was hospitalized with diarrhea with 20-30 BMs/day and dehydration. Task 2: hospitalization for adverse Despite escalated adalimumab dosing (40 mg weekly and later 80 mg Q2 weeks) she remains symptomatic. Her most recent colonoscopy on event adalimumab 80mg Q2 weeks showed pancolitis. She was hospitalized with diarrhea with 20-30 BMs/day and dehydration. Task 3: medication before Despite escalated adalimumab dosing (40 mg weekly and later 80 mg Q2 hospitalization for adverse event weeks) she remains symptomatic. Her most recent colonoscopy on

Figure 1. Example of the three prediction tasks from a clinical note in the corpus. Medications of interest were pre-annotated in blue, hospitalizations in red and signs and symptoms in yellow. Annotators marked up the HPI section where medications of interest predated a hospitalization (green and blue arrow) and AE causing hospitalization (red arrow). Task 3, also referred to as triple, is the combination of Task 1 and Task 2.

adalimumab 80mg Q2 weeks showed pancolitis. She was hospitalized

with diarrhea with 20-30 BMs/day and dehydration.

(triple)

Patients (N=928)		Count(%)
Sex	Female	489 (52.7)
	Male	438 (47.2)
	Nonbinary	1 (0.1)
Age (years)	18-40	460 (49.6)
	41-60	313 (33.7)
	>60	155(16.7)
Ethnicity	Not Hispanic or Latino	832 (89.7)
	Hispanic or Latino	83 (8.9)
	Unknown/Declined	13 (1.4)

Race	White or Caucasian	670 (72.3)
	Asian	78 (8.4)
	Black or African American	41 (4.4)
	American Indian or Alaska Native	9 (1.0)
	Other Pacific Islander	1 (0.1)
	Other and Unknown/Declined	129 (13.9)
IBD Diagnosis	Crohn's disease	735 (79.2)
	Ulcerative colitis	625 (67.4)

Table 1. Characteristics of patients in our note corpus

	Train (%)	Development (%)	Test (%)
# Annotated notes	742 (80)	93 (10)	93 (10)
SAEs present	335 (82)	37 (9)	39 (9)
No SAEs	406 (79)	56 (11)	54 (10)

Table 2. Distribution of number of notes containing an SAE

Non-steroid	Non-steroid	Number of Hospitalizations	Number of SAEs
Immunosuppressant	lmmunosuppressant		
Class			
Anti-TNF	Adalimumab	136	172
	Certolizumab	19	26
	Etanercept	2	1
	Golimumab	2	2
	Infliximab	179	231
JAK-inhi bitor	Tofacitinib	8	8
Anti-IL-12/23	Ustekinumab	100	128
Anti-integrin	Vedolizumab	106	135

 Table 3. Distribution of hospitalizations and SAEs by medication. Anti-tumor necrosis factor (Anti-TNF),

 Janus Kinase-inhibitor (JAK-inhibitor), anti-interleukin-12/23 (anti-IL-12/23).

Serious Adverse Event MedDRA System Organ Class	Steroid Sparing Immunosuppressant Class	Frequency
Infections and infestations	Anti-TNF	66
	Anti-IL 12/23	24
	Anti-integrin	10
	JAKi	2
Failure of intended efficacy	Anti-TNF	216
	Anti-IL 12/23	75
	Anti-integrin	90
	ЈАКі	6
Gastrointestinal disorders	Anti-TNF	25
	Anti-IL 12/23	12
	Anti-integrin	6
	JAKi	0
Neoplasms	Anti-TNF	1
	Anti-IL 12/23	0
	Anti-integrin	0
	JAKi	0
Cardiac disorders	Anti-TNF	8
	Anti-IL 12/23	1
	Anti-integrin	3
	JAKi	0
General disorders and administration site conditions	Anti-TNF	21
	Anti-IL 12/23	1
	Anti-integrin	9
	JAKi	0
Nervous system disorders	Anti-TNF	7
	Anti-IL 12/23	2
	Anti-integrin	2
	ЈАКі	0

Table 4. Top 7 SAEs in the Study. Anti-tumor necrosis factor (Anti-TNF), Janus Kinase-inhibitor (JAKi), anti-interleukin-12/23 (anti-IL-12/23).



Figure 2. Network Graph of SAEs by medication class. The width of lines indicates the strength of association by frequency. The size of the nodes is relative to the number of exposures in our corpus to each medication. SAE colors are indicative of which medication(s) they were associated with. An interactive version of this figure can be found at https://ibd-ade.streamlit.app/

Task	Model	Accuracy	Macro	ТР	TN	FP	FN
		(%)	F1(%)				
Medication	H-UCSF-BERT	88	62	63	1989	173	105
before	CNN	74	49	51	1682	480	117
hospitalization relations	XGBoost	73	51	49	1672	490	119

Hospitalization for SAE relations	H-UCSF-BERT	96	62	79	9603	421	16
	H-UCSF-BERT + only nearby SAEs	92	68	34	1078	41	61
	BiLSTM + only nearby SAEs	93	48	7	1091	28	88
Medication before	H-UCSF-BERT + only nearby SAEs	91	61	141	7790	619	178
hospitalization for SAE relation	CNN + only nearby AEs	94	49	11	8013	396	308
(triples)	BiLSTM + only nearby AEs	95	50	11	7953	456	308

Table 5. Results of UCSF BERT performance on the tasks of SAE detection from real world clinical notes. Results for the three relation tasks to classify whether a pair/triple of specific entities of type medication, hospitalization and adverse event are related. Bolded models correspond to those with the best performance as measured by Macro F1. Only nearby SAEs refer to restricting only SAEs that are mentioned within a two-sentence window of the hospitalization event. Only the best three models are reported. H-UCSF-BERT = Hierarchical University of California San Francisco Bidirectional Encoder Representation from Transformers, TP = true positive, TN = true negative, FP = false positive and FN = false negative.